Background: After 10 years of systematically nationwide applied measures for reduction of infection risk, in this national prospective observational study, we reassessed the prevalence of hepatitis virus infection prevalence and its influence on the outcome of end-stage kidney disease (ESKD) patients treated with hemodialysis. Methods: Six-hundred ESKD patients (332 men and 268 women, median age 56 years) treated with chronic HD in seven centers from all the historical regions of Romania have been assigned to this study on 1st of November 2010. The aims of this study were to reevaluate the prevalence of the hepatitis B and C virus infection in a HD population from Romania after 10 years of systematically nationwide applied measures for reduction of infection risk and also to assess the impact of these infections on the prognosis of HD patients. Results: HBsAg was positive in 9.5% (n = 57) of the patients, anti-HCV antibodies were detected in 27.3% (n = 164) and 5% (n = 30) were positive for both HBV and HCV infection. The mortality risk was significantly influenced only by age, the presence of coronary artery disease and the 25 OH vitamin D levels. Conclusions: This study shows that the systematically nationwide applied measures for reduction of infection risk significantly decreased HV infection prevalence in HD patients in Romania. The presence of HV infection did not significantly influence the mortality risk in this population.

Keywords:
Hepatitis B infection, Hepatitis C infection, Hemodialysis, End-stage kidney disease, Mortality
1.
Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S: Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007;18:1584-1593.
2.
Fabrizi F, Messa P, Martin P: Hepatitis B virus infection and the dialysis patient. Semin Dial 2008;21:440-446.
3.
Annual Report of the Romanian Renal Registry 2012: Ministry of Health - ‘Dr Carol Davila' Nephrology Clinic. Bucharest, Romania, 2013.
4.
Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I, Covic M: Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999;14:40-45.
5.
Vladutiu DS, Cosa A, Neamtu A, State D, Braila M, Gherman M, Patiu IM, Dulau-Florea I: Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat 2000;7:313-319.
6.
van de Luijtgaarden MW, Jager KJ, Stel VS, Kramer A, Cusumano A, Elliott RF, Geue C, MacLeod AM, Stengel B, Covic A, Caskey FJ: Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant 2013;28:1264-1275.
7.
Gheorghe L, Csiki IE, Iacob S, Gheorghe C: The prevalence and risk factors of hepatitis B virus infection in an adult population in Romania: a nationwide survey. Eur J Gastroenterol Hepatol 2013;25:56-64.
8.
Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L: The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006-2008. J Gastrointestin Liver Dis 2010;19:373-379.
9.
Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ: National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005;18:52-61.
10.
Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, Saito A, LaBrecque J, Port FK, Young EW: Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003;63:2222-2229.
11.
Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW: Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65:2335-2342.
12.
Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H: Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006;28:729-735.
13.
Telaku S, Fejza H, Elezi Y, Bicaj T: Hepatitis B and C in dialysis units in Kosova. Virol J 2009;6:72.
14.
Institutul National de Statistica Romania, Repere economice si sociale regionala: statistica teritorială 2013. http://www.insse.ro/cms/ro/content/indicatori-de-statistica-regionala-publicatii.
15.
Natov SN, Lau JY, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS, Pereira BJ: Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group. Am J Kidney Dis 1998;31:920-927.
16.
Demir C, Demir M: Vitamin D levels in patients with chronic hepatitis B virus infection and naturally immunized individuals. Internal Medicine Inside 2013, DOI: 10.7243/2052-6954-1-2.
17.
Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA: Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann Hepatol 2013;12:199-204.
18.
Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, Esteghamati A, Abdollahi A, Mazloumi M: Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int 2010;4:634-640.
19.
Kalantar-Zadeh K, McAllister CJ, Miller LG: Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant 2005;20:1662-1669.
20.
Goral V, Simsek M, Mete N: Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol 2010;16:1639-1643.
21.
Fabrizi F, Dixit V, Messa P: Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012;19:601-607.
22.
Josselson J, Kyser BA, Weir MR, Sadler JH: Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987;9:456-461.
23.
Jha R, Kher BA, Naik S, Elhance R, Gupta A, Sharma RK: Hepatitis B associated liver disease in dialysis patients: role of vaccination. J Nephrol 1993;6:98-103.
24.
Voiculescu M, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D, Radasan A, Micu G, Pertache I: A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania. J Gastrointestin Liver Dis 2010;19:43-48.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.